In a phase III study presented by Shukui Qin, the combination of #immunotherapy plus an anti-angiogenic TKI showed effectiveness as first line therapy for unresectable #HCC and presents a new first-line treatment option. The Chinese study randomized patients to either C (Camrelizumab; anti-PD-1 IgG4 monoclonal antibody) + R (Rivoceranib, Apatinib; VEGFR2-TKI) vs. S (Sorafenib), PFS and OS was significantly improved with C+R vs. S. ORR, DCR and DoR were also better with C+R.
.png)